Human mesenchymal stem cells are susceptible to lysis by CD8+ T cells and NK cells

Cell Transplantation

Volumn 20, Issue 10, 2011, Pages 1547-1559

  Crop, Meindert J ^a   Korevaar, Sander S ^a   de Kuiper, Ronella ^a   Ijzermans, Jan N M ^a   van Besouw, Nicole M ^a   Baan, Carla C ^a   Weimar, Willem ^a   Hoogduijn, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cytotoxicity; Mesenchymal stem cells (MSCS); NK cells; Transplantation

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CYTOTOXIC ANTIBODY; ENDOGLIN; EUROPIUM; THY 1 ANTIGEN;

ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SUSPENSION; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LYSIS; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84855813499     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368910X564076     Document Type: Article

References (49)

1. Aggarwal, S.; Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815-1822; 2005.
2. Angoulvant, D.; Clerc, A.; Benchalal, S.; Galambrun, C.; Farre, A.; Bertrand, Y.; Eljaafari, A. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 41(3-4):469-476; 2004.
3. Asari, S.; Itakura, S.; Ferreri, K.; Liu, C. P.; Kuroda, Y.; Kandeel, F.; Mullen, Y. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 37(5):604-615; 2009.
4. Badillo, A. T.; Beggs, K. J.; Javazon, E. H.; Tebbets, J. C.; Flake, A. W. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol. Blood Marrow Transplant. 13(4):412-422; 2007.
5. Bartholomew, A.; Sturgeon, C.; Siatskas, M.; Ferrer, K.; McIntosh, K.; Patil, S.; Hardy, W.; Devine, S.; Ucker, D.; Deans, R.; Moseley, A.; Hoffman, R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and pro- long skin graft survival in vivo. Exp. Hematol. 30(1):42-48; 2002.
6. Beggs, K. J.; Lyubimov, A.; Borneman, J. N.; Bartholomew, A.; Moseley, A.; Dodds, R.; Archambault, M. P.; Smith, A. K.; McIntosh, K. R. Immunologic consequences of multiple, high-dose administration of allogeneic mesen- chymal stem cells to baboons. Cell Transplant. 15(8-9): 711-721; 2006.
7. Bouma, G. J.; van der Meer-Prins, P. M.; van Bree, F. P.; van Rood, J. J.; Claas, F. H. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum. Immunol. 35(2):85-92; 1992.
8. Cao, Y.; Luetkens, T.; Kobold, S.; Hildebrandt, Y.; Gordic, M.; Lajmi, N.; Meyer, S.; Bartels, K.; Zander, A. R.; Bokemeyer, C.; Kroger, N.; Atanackovic, D. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp. Hematol. 38(10):860-867; 2010.
9. Casiraghi, F.; Azzollini, N.; Cassis, P.; Imberti, B.; Morigi, M.; Cugini, D.; Cavinato, R. A.; Todeschini, M.; Solini, S.; Sonzogni, A.; Perico, N.; Remuzzi, G.; Noris, M. Pretransplant infusion of mesenchymal stem cells pro- longs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181(6):3933-3946; 2008.
10. Christensen, M. E.; Turner, B. E.; Sinfield, L. J.; Kollar, K.; Cullup, H.; Waterhouse, N. J.; Hart, D. N.; Atkinson, K.; Rice, A. M. Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft- versus-host disease. Haematologica 95(12):2102-2110; 2010.
11. Corcione, A.; Benvenuto, F.; Ferretti, E.; Giunti, D.; Cappiello, V.; Cazzanti, F.; Risso, M.; Gualandi, F.; Mancardi, G. L.; Pistoia, V.; Uccelli, A. Human mesenchymal stem cells modulate B-cell functions. Blood 107(1):367-372; 2006.
12. Crop, M. J.; Baan, C. C.; Korevaar, S. S.; Ijzermans, J. N.; Alwayn, I. P.; Weimar, W.; Hoogduijn, M. J. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 87(6): 896-906; 2009.
13. Crop, M. J.; Baan, C. C.; Korevaar, S. S.; Ijzermans, J. N.; Pescatori, M.; Stubbs, A. P.; van Ijcken, W. F.; Dahlke, M. H.; Eggenhofer, E.; Weimar, W.; Hoogduijn, M. J. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin. Exp. Immunol. 162(3):474-486; 2010.
14. Dahlke, M. H.; Hoogduijn, M.; Eggenhofer, E.; Popp, F. C.; Renner, P.; Slowik, P.; Rosenauer, A.; Piso, P.; Geissler, E. K.; Lange, C.; Chabannes, D.; Mazzanti, B.; Bigenzahn, S.; Bertolino, P.; Kunter, U.; Introna, M.; Rambaldi, A.; Capelli, C.; Perico, N.; Casiraghi, F.; Noris, M.; Gotti, E.; Seifert, M.; Saccardi, R.; Verspaget, H. W.; van Hoek, B.; Bartholomew, A.; Wekerle, T.; Volk, H. D.; Remuzzi, G.; Deans, R.; Lazarus, H.; Schlitt, H. J.; Baan, C. C. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Trans- plantation 88(5):614-619; 2009.
15. Ding, Y.; Xu, D.; Feng, G.; Bushell, A.; Muschel, R. J.; Wood, K. J. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 58(8):1797-1806; 2009.
16. Di Nicola, M.; Carlo-Stella, C.; Magni, M.; Milanesi, M.; Longoni, P. D.; Matteucci, P.; Grisanti, S.; Gianni, A. M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10):3838-3843; 2002.
17. Eliopoulos, N.; Stagg, J.; Lejeune, L.; Pommey, S.; Galipeau, J. Allogeneic marrow stromal cells are immune rejected by MHC class Iand class II-mismatched recipient mice. Blood 106(13):4057-4065; 2005.
18. Fiorina, P.; Jurewicz, M.; Augello, A.; Vergani, A.; Dada, S.; La Rosa, S.; Selig, M.; Godwin, J.; Law, K.; Placidi, C.; Smith, R. N.; Capella, C.; Rodig, S.; Adra, C. N.; Atkinson, M.; Sayegh, M. H.; Abdi, R. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J. Immunol. 183(2):993-1004; 2009.
19. Freedman, M. S.; Bar-Or, A.; Atkins, H. L.; Karussis, D.; Frassoni, F.; Lazarus, H.; Scolding, N.; Slavin, S.; Le Blanc, K.; Uccelli, A. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multi- ple sclerosis: Consensus report of the International MSCT Study Group. Mult. Scler. 16(4):503-510; 2010.
20. Giordano, A.; Galderisi, U.; Marino, I. R. From the labo- ratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 211(1):27-35; 2007.
21. Gonzalez, M. A.; Gonzalez-Rey, E.; Rico, L.; Buscher, D.; Delgado, M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136(3):978-989; 2009.
22. Hemeda, H.; Jakob, M.; Ludwig, A.; Giebel, B.; Lang, S.; Brandau, S. Interferon-gamma and tumor necrosis factoralpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. Stem Cells Dev. 19(5):693-706; 2010.
23. Hoogduijn, M. J.; Crop, M. J.; Peeters, A. M.; Korevaar, S. S.; Eijken, M.; Drabbels, J. J.; Roelen, D. L.; Maat, A. P.; Balk, A. H.; Weimar, W.; Baan, C. C. Donorderived mesenchymal stem cells remain present and func- tional in the transplanted human heart. Am. J. Transplant. 9(1):222-230; 2009.
24. Hoogduijn, M. J.; Crop, M. J.; Peeters, A. M.; Van Osch, G. J.; Balk, A. H.; Ijzermans, J. N.; Weimar, W.; Baan, C. C. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev. 16(4):597-604; 2007.
25. Hoogduijn, M. J.; Popp, F. C.; Grohnert, A.; Crop, M. J.; van Rhijn, M.; Rowshani, A. T.; Eggenhofer, E.; Renner, P.; Reinders, M. E.; Rabelink, T. J.; van der Laan, L. J.; Dor, F. J.; Ijzermans, J. N.; Genever, P. G.; Lange, C.; Durrbach, A.; Houtgraaf, J. H.; Christ, B.; Seifert, M.; Shagidulin, M.; Donckier, V.; Deans, R.; Ringden, O.; Perico, N.; Remuzzi, G.; Bartholomew, A.; Schlitt, H. J.; Weimar, W.; Baan, C. C.; Dahlke, M. H. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 90(2):124-126; 2010.
26. Jewett, A.; Arasteh, A.; Tseng, H. C.; Behel, A.; Arasteh, H.; Yang, W.; Cacalano, N. A.; Paranjpe, A. Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity. PLoS One 5(3):e9874; 2010.
27. Krampera, M.; Cosmi, L.; Angeli, R.; Pasini, A.; Liotta, F.; Andreini, A.; Santarlasci, V.; Mazzinghi, B.; Pizzolo, G.; Vinante, F.; Romagnani, P.; Maggi, E.; Romagnani, S.; Annunziato, F. Role for interferon-gamma in the im- munomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24(2):386-398; 2006.
28. Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M. E.; Remberger, M.; Dini, G.; Egeler, R. M.; Bacigalupo, A.; Fibbe, W.; Ringden, O. Mesenchymal stem cells for treat- ment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371(9624):1579-1586; 2008.
29. Le Blanc, K.; Tammik, C.; Rosendahl, K.; Zetterberg, E.; Ringden, O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31(10):890-896; 2003.
30. Morigi, M.; Introna, M.; Imberti, B.; Corna, D.; Abbate, M.; Rota, C.; Rottoli, D.; Benigni, A.; Perico, N.; Zoja, C.; Rambaldi, A.; Remuzzi, A.; Remuzzi, G. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 26(8):2075-2082; 2008.
31. Najar, M.; Rouas, R.; Raicevic, G.; Boufker, H. I.; Lewalle, P.; Meuleman, N.; Bron, D.; Toungouz, M.; Martiat, P.; Lagneaux, L. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11(5):570-583; 2009.
32. Nauta, A. J.; Westerhuis, G.; Kruisselbrink, A. B.; Lurvink, E. G.; Willemze, R.; Fibbe, W. E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 108(6):2114-2120; 2006.
33. Nohroudi, K.; Arnhold, S.; Berhorn, T.; Addicks, K.; Hoehn, M.; Himmelreich, U. In vivo MRI stem cell tracking requires balancing of detection limit and cell viability. Cell Transplant. 19(4):431-441; 2010.
34. Pende, D.; Cantoni, C.; Rivera, P.; Vitale, M.; Castriconi, R.; Marcenaro, S.; Nanni, M.; Biassoni, R.; Bottino, C.; Moretta, A.; Moretta, L. Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur. J. Immunol. 31(4): 1076-1086; 2001.
35. Poggi, A.; Prevosto, C.; Zancolli, M.; Canevali, P.; Musso, A.; Zocchi, M. R. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells. Ann. NY Acad. Sci. 1109:47-57; 2007.
36. Polchert, D.; Sobinsky, J.; Douglas, G.; Kidd, M.; Moadsiri, A.; Reina, E.; Genrich, K.; Mehrotra, S.; Setty, S.; Smith, B.; Bartholomew, A. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38(6):1745-1755; 2008.
37. Popp, F. C.; Eggenhofer, E.; Renner, P.; Slowik, P.; Lang, S. A.; Kaspar, H.; Geissler, E. K.; Piso, P.; Schlitt, H. J.; Dahlke, M. H. Mesenchymal stem cells can induce longterm acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl. Immunol. 20(1-2):55-60; 2008.
38. Rasmusson, I.; Ringden, O.; Sundberg, B.; Le Blanc, K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76(8):1208-1213; 2003.
39. Rasmusson, I.; Uhlin, M.; Le Blanc, K.; Levitsky, V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J. Leukoc. Biol. 82(4):887-893; 2007.
40. Selmani, Z.; Naji, A.; Zidi, I.; Favier, B.; Gaiffe, E.; Obert, L.; Borg, C.; Saas, P.; Tiberghien, P.; Rouas-Freiss, N.; Carosella, E. D.; Deschaseaux, F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulartory T cells. Stem Cells 26(1):212-222; 2008.
41. Semedo, P.; Palasio, C. G.; Oliveira, C. D.; Feitoza, C. Q.; Goncalves, G. M.; Cenedeze, M. A.; Wang, P. M.; Teixeira, V. P.; Reis, M. A.; Pacheco-Silva, A.; Camara, N. O. Early modulation of inflammation by mesenchymal stem cell after acute kidney injury. Int. Immunopharmacol. 9(6):677-682; 2009.
42. Sotiropoulou, P. A.; Perez, S. A.; Gritzapis, A. D.; Baxevanis, C. N.; Papamichail, M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24(1):74-85; 2006.
43. Spaggiari, G. M.; Capobianco, A.; Abdelrazik, H.; Becchetti, F.; Mingari, M. C.; Moretta, L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxy- genase and prostaglandin E2. Blood 111(3):1327-1333; 2008.
44. Spaggiari, G. M.; Capobianco, A.; Becchetti, S.; Mingari, M. C.; Moretta, L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2- induced NK-cell proliferation. Blood 107(4):1484-1490; 2006.
45. Tabera, S.; Perez-Simon, J. A.; Diez-Campelo, M.; Sanchez-Abarca, L. I.; Blanco, B.; Lopez, A.; Benito, A.; Ocio, E.; Sanchez-Guijo, F. M.; Canizo, C.; San Miguel, J. F. The effect of mesenchymal stem cells on the viabil- ity, proliferation and differentiation of B-lymphocytes. Haematologica 93(9):1301-1309; 2008.
46. Togel, F.; Hu, Z.; Weiss, K.; Isaac, J.; Lange, C.; Westen- felder, C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 289(1):F31-42; 2005.
47. van Besouw, N. M.; van der Mast, B. J.; de Kuiper, P.; Smak Gregoor, P. J.; Vaessen, L. M.; IJzermans, J. N.; van Gelder, T.; Weimar, W. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immuno- suppressive therapy can be safely reduced. Transplantation 70(1):136-143; 2000.
48. Yagi, H.; Soto-Gutierrez, A.; Parekkadan, B.; Kitagawa, Y.; Tompkins, R. G.; Kobayashi, N.; Yarmush, M. L. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 19(6):667-679; 2010.
49. Yen, B. L.; Chang, C. J.; Liu, K. J.; Chen, Y. C.; Hu, H. I.; Bai, C. H.; Yen, M. L. Brief report-human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells 27(2):451-456; 2009.